Literature DB >> 1928268

Microbiologic aspects of fluoroquinolones.

H C Neu1.   

Abstract

Fluoroquinolones are both old and new antimicrobial agents. The prototype agent of the class, nalidixic acid, was synthesized in 1962, whereas the new fluoroquinolones began to be used in the latter 1980s. During the past six years, orally administered fluoroquinolones have been used extensively in Japan and Europe to treat both community- and hospital-acquired infections. Most recently, one of the fluoroquinolones, ciprofloxacin, has also become available for parenteral and topical ophthalmic use. This article reviews the chemistry, antimicrobial activity, pharmacology, and clinical use of the fluoroquinolones.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1928268

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  9 in total

1.  In vitro antibiotic resistance in bacterial keratitis in London.

Authors:  S J Tuft; M Matheson
Journal:  Br J Ophthalmol       Date:  2000-07       Impact factor: 4.638

2.  Microbial keratitis: what's the preferred initial therapy? View 2: Empirical fluoroquinolone therapy is sufficient initial treatment.

Authors:  N Morlet; M Daniell
Journal:  Br J Ophthalmol       Date:  2003-09       Impact factor: 4.638

3.  Ocular penetration of topical ciprofloxacin and norfloxacin drops and their effect upon eyelid flora.

Authors:  J P Leeming; J P Diamond; R Trigg; L White; H B Hoh; D L Easty
Journal:  Br J Ophthalmol       Date:  1994-07       Impact factor: 4.638

4.  Identification and antibiotic susceptibility of coagulase negative staphylococci isolated in corneal/external infections.

Authors:  A Pinna; S Zanetti; M Sotgiu; L A Sechi; G Fadda; F Carta
Journal:  Br J Ophthalmol       Date:  1999-07       Impact factor: 4.638

Review 5.  Fluoroquinolones: place in ocular therapy.

Authors:  A Smith; P M Pennefather; S B Kaye; C A Hart
Journal:  Drugs       Date:  2001       Impact factor: 9.546

6.  Paediatric bacterial keratitis cases in Shanghai: microbiological profile, antibiotic susceptibility and visual outcomes.

Authors:  J Hong; J Chen; X Sun; S X Deng; L Chen; L Gong; W Cao; X Yu; J Xu
Journal:  Eye (Lond)       Date:  2012-10-19       Impact factor: 3.775

Review 7.  Pharmacokinetic considerations in the treatment of bacterial keratitis.

Authors:  M C Callegan; R J O'Callaghan; J M Hill
Journal:  Clin Pharmacokinet       Date:  1994-08       Impact factor: 6.447

8.  Topical 0.3% ciprofloxacin, norfloxacin, and ofloxacin in treatment of bacterial keratitis: a new method for comparative evaluation of ocular drug penetration.

Authors:  J P Diamond; L White; J P Leeming; H Bing Hoh; D L Easty
Journal:  Br J Ophthalmol       Date:  1995-06       Impact factor: 4.638

9.  Mutations in the quinolone resistance determining region in Staphylococcus epidermidis recovered from conjunctiva and their association with susceptibility to various fluoroquinolones.

Authors:  M Yamada; J Yoshida; S Hatou; T Yoshida; Y Minagawa
Journal:  Br J Ophthalmol       Date:  2008-05-06       Impact factor: 4.638

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.